What is MoonLake Immunotherapeutics's interest paid?

MoonLake Immunotherapeutics (MLTX) reported interest paid of $1.82M in Q1 2026.

What does interest paid mean?

Supplemental disclosure of total cash interest paid on all debt and lease obligations during the period.

MoonLake Immunotherapeutics MLTX Interest Paid

Interest Paid at other companies

AnaptysBio, Inc.ANAB

$20.83M+15.1%

Opko HealthOPK

$9.6M-30.2%

Kymera TherapeuticsKYMR

$65K-15.6%

Arcutis Biotherapeutics, Inc.ARQT

$2.91M+13.2%

ImmunityBio, Inc.IBRX

$20.12M+29.0%

Johnson & JohnsonJNJ

$465.75M-2.5%

Other financials

Income statement

See full

Operating income-$70.0M-47.5%

Net income-$69.7M-74.5%

EPS (diluted)-$0.98-55.6%

Balance sheet

See full

Cash & equivalents$298.5M+9.9%

Total debt$100.8M+33.3%

Total equity$254.0M-37.7%

Total assets$400.4M-21.7%

Cash flow

See full

Operating cash flow-$66.3M-73.8%

CapEx--100%

Free cash flow-$66.3M-73.6%

Valuation

See full

Market cap$1.49B-45.9%

Enterprise value$1.29B-50.0%

Returns & leverage

See full

Return on equity-77.7%-221pp

Debt / equity0.4×+0.2×

Current ratio8.6×-12.5×

Where this comes from

Reported directly by MoonLake Immunotherapeutics in its filing.

Tagged under the XBRL concept us-gaap:InterestPaidNet.

The official record: MoonLake Immunotherapeutics’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →

Ask your AI about MoonLake Immunotherapeutics's interest paid.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is MoonLake Immunotherapeutics's interest paid?: MoonLake Immunotherapeutics (MLTX) reported interest paid of $1.82M in Q1 2026.
What does interest paid mean?: Supplemental disclosure of total cash interest paid on all debt and lease obligations during the period.